Patent 256/301



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:) Oroup Art Unit: 2161
Glen J. Anderson) Examiner: Not yet assigned
Serial No.: 09/751,890)
Filed: December 27, 1000)
For: A Method and System for Providing and Updating Customized Health Care Information Based on an Individual's Genome)))

INFORMATION DISCLOSURE STATEMENT

Box Non-Fee Commissioner for Patents Washington, D.C. 20231 APR 3 0 2001
Technology Contactor

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

\boxtimes	This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1)
within	three months of the filing date of the application, which is not a continued prosecution application
	CERTIFICATE OF MAILING
	(37 C.F.R. §1.8a)
I hereby date show	certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the wn below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.
	Sall Hartwell

April 23, 2001

Date of Deposit

1.491; or (3) befo	ore the mailing of a first Office action on the merits; or (4) before the mailing of a first or filing a request for continued examination under § 1.114. Thus, no fee is required.
th	owever, if the undersigned is in error in this regard, Applicant respectfully requests at the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and harge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.
th	owever, if the undersigned is in error in this regard, Applicant respectfully requests at the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a atement under 37 CFR § 1.97(e) is included below, thus no fee is required.
	is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR
TI	he fee due under 37 CFR § 1.17(p) is submitted herewith.
ev th to	statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the vent that this IDS is not received before a Final Action or a Notice of Allowance, ten Applicant respectfully requests that the Office consider the filing of these papers be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR 1.17(p) to the deposit account below.
§ 1.113 or a Notic	is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR ce of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted
	STATEMENT UNDER 37 CFR § 1.97(e):
	n contained in this IDS was first cited in any communication from a foreign patent office
in a counterpart for	oreign application not more than three months prior to the filing of this IDS.
No item c	contained in this IDS was cited in a communication from a foreign patent office in a
counterpart foreig	gn application, and, to the knowledge of the person signing this statement after making
reasonable inquir	y, no item of information contained in this IDS was known to any individual designated
in 37 CFR § 1.56	(c) more than three months prior to the filing of this IDS.

PAYMENT	AND/OR A	UTHORIZATION	ON TO	CHARGE I	FEES:
----------------	----------	--------------	-------	----------	-------

r the above fee(s).
t No. 50-0439 for the above fee(s).
quired by the filing of these papers, and to credit
No. 50-0439 .
Respectfully submitted, LYON & LYON LLP
By: Ivan Posey Reg. No. 43,865

Enclosures: 14 Prior Art References

22249

LYON & LYON LLP 633 W. Fifth Street, Suite 4700 Los Angeles, CA 90071

FORM PTO-1449	ATTY. DOCKET NO. 256/301	SERIAL NO. 09/751,890
JIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S	APPLICANT:	037731,034
O / DESCRIPTION DISCLOSURE STATEMENT	Glen J. Anderson	<u> </u>
(m)	FILING DATE:	GROUP:
(Use several sheets if necessary)	December 27, 1000	2161
2 6 m 2		

XAMENA INITIAL	all or	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	1.	5,590,648	1/7/1997	Mitchell, et al.			
	2.	5,722,418	3/3/1998	Bro			
	3.	5,732,709	3/31/1998	Tackline, et al.			·
	4.	5,748,907	5/5/1998	Crane		-	
	5.	5,911,687	6/15/1999	Sato, et al.			· · ·
	6.	5,995,937	11/30/1999	DeBusk			
	7.	6,014,631	1/11/2000	Teagarden, et al.			

			FOREIGN P	ATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS YES	LATION NO
	ΑI		:	NECE	VED			
	AJ			APR 3 0	2001			
	AK			Technology Can	3r 2100			

	Copyright 2000 Responsive Database Services, Inc., Business and Industry, "DNA Detectives", pp. 1-10,
8.	http://web.lexis-nexis.com/In.universe
	Copyright 2000 Mainichi Daily News, "Gene counseling sadly lags behind Technology", pp. 1-2, May 26, 2000
9.	http://web.lexis-nexis.com/In.universe
, lo.	CNN.com Health, "Your Health: Implications of the Human Genome Project", http://www.cnn, March 17, 200
10.	CNN.com Health, Jeffrey P. Khan, "Who owns your genes?", March 21, 2000,
11.	
	CNN.com technology > computing, "Have your genes sequenced online", May 24, 2000,
12.	
	CNN.com Health, "Milestone in human genetics to be announced Monday", June 23, 2000,
13.	

EXAMINER:	DATE CONSIDERED:
Not yet assigned	
EVALUATED Initial if reference is considered subother of	or not citation is in conformance with MPEP 609.

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant